

In re Application of:

Juergen ROEMISCH et al.

Application No.: 09/632,627

Filed: August 4, 2000

For: PROCESS FOR THE PREPARATION IN
PURE FORM OF THE PROTEASE ACTIVATING
BLOOD CLOTTING FACTOR VII, ITS
PROENZYME OR A MIXTURE OF BOTH
PROTEINS BY MEANS OF ION EXCHANGE
CHROMATOGRAPHY

Group Art Unit: 1653

Examiner: Samuel W. Liu

BOX AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is being filed in response to a telephonic interview with the Examiner on July 28, 2003, informing Applicants of the need to comply with the requirements for applications containing sequence disclosures set forth in 37 C.F.R. §§ 1.821-825. It is accompanied by a printed Sequence Listing, a computer readable form of the Sequence Listing, and a Statement to Support Filing.

Amendments to the Specification are included in this paper.

Remarks follow the amendment section of this paper.


**FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP**

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Attachments to this amendment include a printed Sequence Listing, a computer readable form of the Sequence Listing and a Statement to Support Filing.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as follows:

Please insert the attached Sequence Listing (pages 1-2) at the end of the application.

Please delete the paragraph on page 1, lines 12-29 and replace it with the following paragraph:

German patent application 19 903 693.4 has already disclosed a protease for the activation of blood clotting factor VII, a process for its production, for its detection and for its inactivation, and pharmaceutical preparations which contain this protease. This protease, first isolated from plasma, occurs there together with a nonactivated form, which is designated below as "proenzyme". The protease activates blood clotting factor VII and accelerates clotting, as has been shown by numerous experiments. In the further investigation of the biological properties of this protein, identified as serine protease, it emerged that single-chain plasminogen activators, such as prourokinase, are also effectively activated. Moreover, inactivation of factors V and VIII in vitro was observed. In addition to the sequenced regions already described in German patent application 19 903 693.4, N-terminal sequencings of protease fractions were carried out. The following amino acid sequences characterize the FVII-activating protease: IYGGFKSTAGKHP (SEQ ID NO: 1); LLESLDPDXTDP (SEQ ID NO: 2); EFHEQSFRVEKI (SEQ ID NO: 3); SKFTXAXPXQFK (SEQ ID NO: 4); where X means not identified. The sequences of the protease mentioned elucidated up to now show that they agree 100% with sequences of the protease published by Choi-Miura (Choi-Miura at al. J. Biochem. 1996; 119: 1157 to 1165).

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

REMARKS

The Office has indicated that the application, as filed, does not comply with the requirements of 37 C.F.R. §§ 1.821 - 1.825. Applicants have amended the application to insert the Sequence Listing as noted above. No new matter is added.

A copy of the Sequence Listing in computer readable form is also attached, accompanied by a verified statement that the paper and computer readable copies of the Sequence Listing are the same and that no new matter has been added. Applicants submit that the requirements of 37 C.F.R. §§ 1.821 - 1.825 have now been met.


Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 31, 2003

By:


Sanya Sukduang
Reg. No. 46390

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

569228_1